St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD?
As throughout this conference, talks toggled between what’s known in LOAD and eFAD, comparing all the while how well knowledge on these forms of AD matches up...
ALL NEWS
466 RESULTS
Sort By:
- Most Recent
- Most Commented
Stayin’ Alive—Huge Study Quickens Quest for Plasma AD Biomarker
Identifying people on the verge of dementia before they actually succumb has become somewhat of a Holy Grail for Alzheimer disease research...
Research Brief: ALS Leaves a Footprint in the Blood
Many researchers studying neurodegenerative disease focus their studies on the affected organs of the nervous system. But in doing so, they may be ignoring a more accessible place...
Uppsala: Brainstorming Biomarkers
Biomarkers were top of the agenda on the second day of Neurodegenerative Disorders—Immunotherapy and Biomarkers...
Vienna: New Tack to See Amyloid Oligomers in Body Fluids
The ICAD featured that the interest in small Aβ aggregates has branched out far beyond the initial debates about whether they even exist and which forms are important...
Uppsala: Immunotherapy and Biomarkers Take Center Stage
In addition to immunotherapy, a meeting in Uppsala, Sweden, focused on recent progress in the development of novel disease biomarkers...
Subjective Memory Complaint—Not So Subjective Anymore?
People who complain of troubling memory lapses but show no impairment in standard memory tests may take some solace from a recent European study...
Seeking a Reliable Yardstick for ALS Trials
To determine if a medicine works, scientists need reliable patient data, but the right numbers are not always easy to come by...
Research Brief: APL1β28—Surrogate for CNS Aβ42 Production?
Calculating the risk of impending AD based on levels of CSF Aβ42 has been tricky because the peptide forms insoluble aggregates that muddle estimates of its production rate in the CNS...
Meet Progranulin, The Biomarker—A Simpler Story?
Scientists wrestling the complexities of α-synuclein fluid biochemistry might be forgiven for looking with some envy to a different protein of the neurodegenerative disease spectrum...
Still Early Days for α-synuclein Fluid Marker
Well over a decade of research into fluid biomarker candidates has reached a point where a so-called “pathological signature” of amyloid-β and tau proteins is beginning to emerge...
Ordnung, Please—Can Biomarkers Tame a Bewildering Overlap?
Tangible progress in dealing with spectrum diseases will remain limited until the field comes up with more and better biomarkers of their component proteins...
ADNI: Mission Creep From Alzheimer Disease to Healthy Senior?
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was originally conceived as an exploratory project to identify the best measures for tracking disease progression...
ADNI: One-year Data Narrow Field of MRI, FDG-PET Approaches
Alzheimer imaging aficionados gathered for a peek at the latest data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)...
HAI Seattle: Biomarkers Closing in on AD Pathological Sequence?
The earliest pathological underpinnings of Alzheimer disease often precede symptoms by untold numbers of years, presenting researchers with a two-edged sword...